NCT07156578
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Enrolling by Invitation
PHASE2Ages 12+InterventionalTreatmentRhythm Pharmaceuticals, Inc.
~25 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Bivamelagon
At a glance
Recruiting sites
0 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of bivamelagon as assessed by the number and frequency of AEs
Measured over Baseline to up to 2 years
Conditions
Where it's being run
9 sites across 7 statesUnited Kingdom3
Colorado1
Iowa1
Massachusetts1
New York1
North Carolina1
Tennessee1
Study leadership
- David Meeker, MD · STUDY_CHAIR · Rhythm Pharmaceuticals, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Completed LG-MCCL005 and participant demonstrated adequate safety and tolerability in that study as determined by the Investigator.
Agree to use a highly effective form of contraception and follow contraception requirements throughout the study and for 90 days after.
Exclusion
Willing to remain off of: CYP3A4 inhibitors, strong CYP3A4 inducers, and P-glycoprotein inhibitors or substrates for the duration of the study.
In the opinion of the Investigator, participant is not suitable to participate in the study.
What this trial measures
- Safety and tolerability of bivamelagon as assessed by the number and frequency of AEsBaseline to up to 2 years